Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an ...

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy ...

Health plan sponsors are also expected to see a reduction in the net cost per prescription of GLP-1 medications to treat obesity.

Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of the medication.

Cigna subsidiary Evernorth Health Services will automate prior authorizations for GLP-1 weight-loss drugs under a new program ...

Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it. Recent clinical trial results Eli Lilly released suggest that it is building a lead in ...

Cigna's pharmacy benefits company, Evernorth, reached pricing deals with Eli Lilly and Novo Nordisk to reduce expenses and ...

The CMS last month declined to include anti-obesity medications in its Medicare coverage for Part D, a move that Lilly says ...

Cigna’s (NYSE:CI) health services arm, Evernorth, has launched a pharmacy benefit program that caps out-of-pocket costs at $200 per month for patients using the weight-loss drugs - Wegovy from Novo ...

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...

Today is a big day in drugs. It’s when the US Food and Drug Administration shuts down an emergency measure that allows pharmacies to sell copies of the most widely prescribed weight-loss injection.